Alvogen is an American pharmaceuticals company founded in 2009. In 2014 a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.
|Headquarters||Pine Brook, New Jersey|
|Revenue||$1.1 billion (2017)|
|Owners||CVC Capital Partners and Temasek Holdings|
Number of employees
Alvogen was founded in 2009 by Robert Wessman, who stepped down from his position as CEO of Actavis in order to found the company. Soon after its founding it had 200 products in development. Since 2012 Alvogen has acquired three different companies in Taiwan and South Korea (Alvogen Korea), where it operates as Lotus Pharmaceuticals (which Alvogen purchased in 2014 for $200 million) and is listed on Taipei Stock Exchange (1795.TT). }</ref> In 2015 Alvogen acquired DreamPharma for $187 million. It is also the parent company of Norwich Pharmaceuticals, which does the firm's manufacturing.
In 2015 a controlling interest in Alvogen was acquired by CVC Capital Partners and the Singapore sovereign fund Temasek. As of 2017, the company had 2800 employees spread over thirty-five countries. In 2016 Alvogen also acquired the US company County Line Pharmaceuticals for $300 million. In 2017 Alvogen was valued at $4 billion.
Alvogen markets 350 different products including generic drugs, branded medicines, biosimilar products, cosmetics, and food supplements, for areas including oncology, cardiology, respiratory and neurology. Much of its products for European markets are manufactured at a factory in Romania, and packaged in Serbia. Companies that market their products through Alvogen or have sold their generic drugs to Alvogen for sale, include Bayer, Mylan, Natco, and Pfizer.
In 2017 Alvogen partnered with Vivus to provide the anti-obesity drug phentermine/topiramate to the South Korean market and partnered with Omega Bittner to provide products in the Russian market. In 2017 Alvogen also became the first company to bring a generic oseltamivir to the US market. That year Alvogen had 75 additional products under review with the FDA for approval for sale in the US market.
Alvogen has a subsidiary company called Alvotech that researches biosimilars, which was founded in 2013 by Alvogen founder Robert Wessman. It expects to launch its product line in 2020, committing $300 million to its research and development. Alvotech is based out of Iceland, where it has four research and production sites.
- "Company Overview of Alvogen, Inc". Bloomberg. Retrieved 21 July 2018.
- "Alvogen to buy U.S. drugmaker County Line for $300 million: sources". Reuters. 7 March 2016 – via Reuters.
- Isenberg, Daniel (9 July 2013). Worthless, Impossible and Stupid: How Contrarian Entrepreneurs Create and Capture Extraordinary Value. Harvard Business Review Press. ISBN 9781422186985 – via Google Books.
- Strother, Judith B.; Ulijn, Jan M.; Fazal, Zohra (2 October 2012). Information Overload: An International Challenge for Professional Engineers and Technical Communicators. John Wiley & Sons. ISBN 9781118360507 – via Google Books.
- "Alvogen Partially Acquires Lotus Pharma For US$200 Million". 3 January 2014.
- "Alvogen Acquiring DreamPharma for $187M - GEN". GEN. 2014-08-06.
- "Norwich Pharmaceuticals, An Alvogen Company, celebrates expansion".
- "County Line Pharmaceuticals to be acquired by Alvogen for $300 million".
- "CVC to Explore Options for $4 Billion Drugmaker Alvogen". 26 September 2017 – via www.bloomberg.com.
- Letter, The Pharma. "Alvogen acquires five hormonal products from Bayer". www.thepharmaletter.com.
- "Mylan to Sell Seven Generics to Alvogen as FTC Clears Perrigo Deal - GEN". GEN. 2015-11-04.
- Market, Capital (3 November 2017). "Natco's partner Alvogen to market generic Oseltamivir phosphate power for oral suspension". Business Standard India – via Business Standard.
- Letter, The Pharma. "Alvogen to buy product portfolio from Pfizer". www.thepharmaletter.com.
- "VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug". 6 September 2017.
- Letter, The Pharma. "Alvogen adds Qsymia to its anti-obesity portfolio in South Korea". www.thepharmaletter.com.
- Letter, The Pharma. "Alvogen to expand Russian business with acquisition". www.thepharmaletter.com.
- "Award Winner".
- Letter, The Pharma. "Amneal's generic Tamiflu now available in USA". www.thepharmaletter.com.
- "Alvogen gets US FDA nod to market antiviral drug". ehealth.eletsonline.com.
- "The story of Alvogen and the founding of a pharma empire".